financetom
Business
financetom
/
Business
/
Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning
Nov 17, 2025 7:32 AM

Shares of Tonix Pharmaceuticals Holding Corp ( TNXP ) are trading higher Monday morning after the company announced the U.S. commercial availability of its new drug, TONMYA. Here’s what investors need to know.

TNXP is trading higher today. See what the experts say here.

What To Know: The announcement marks a major milestone, as Tonix says TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years. The drug is a non-opioid analgesic, designed to treat the widespread pain that is a core symptom of the disease.

CEO Seth Lederman stated the launch provides a novel treatment for the estimated 10 million U.S. adults living with fibromyalgia. The FDA approved the drug on Aug. 15, following two Phase 3 trials that demonstrated a significant reduction in daily pain scores compared to placebo.

This commercial rollout follows the company's Nov. 10 earnings report, which included a revenue beat ($3.29 million actual, versus $2.30 million estimated). The launch provides investors with a new, key revenue driver for the biotechnology company.

Benzinga Edge Rankings: According to Benzinga Edge rankings, Tonix currently has a Momentum score of 22.63.

TNXP Price Action: Tonix shares were up 6.48% at $16.93 at the time of publication on Monday, according to Benzinga Pro data.

Read Also: Steve Eisman Disagrees With Michael Burry On AI Depreciation Math: ‘Don’t Think His Concerns Matter That Much’

How To Buy TNXP Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Tonix Pharmaceuticals’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MetroCity Bankshares, First IC to Merge Via $206 Million Cash, Stock Transaction
MetroCity Bankshares, First IC to Merge Via $206 Million Cash, Stock Transaction
Mar 17, 2025
09:57 AM EDT, 03/17/2025 (MT Newswires) -- MetroCity Bankshares ( MCBS ) said Monday it signed a definite merger deal to acquire First IC, the parent company of First IC Bank based in Doraville, Georgia, for roughly $206 million in cash and stock, subject to closing adjustments. Based on MetroCity's closing share price on Friday of $27.78 apiece, the deal...
Robinhood Markets Launches Prediction Markets Hub to Trade Event Outcomes
Robinhood Markets Launches Prediction Markets Hub to Trade Event Outcomes
Mar 17, 2025
09:54 AM EDT, 03/17/2025 (MT Newswires) -- Robinhood Markets ( HOOD ) on Monday launched a prediction markets hub within its app, allowing users to trade on event outcomes. At launch, the hub will allow customers to trade contracts for what the upper bound of the target fed funds rate will be in May, as well as for upcoming men's...
Kratos Defense Receives $3.4 Million From US Navy for Contractor Logistics Support, Engineering Services Contract
Kratos Defense Receives $3.4 Million From US Navy for Contractor Logistics Support, Engineering Services Contract
Mar 17, 2025
09:59 AM EDT, 03/17/2025 (MT Newswires) -- Kratos Defense & Security Solutions (KTOS) said Monday it was awarded about $3.4 million from the US Navy for the base year of a contractor logistics support and engineering services contract for the BQM-177A subsonic aerial target system. The contract has a potential value of up to $19.1 million if all four option...
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy
Mar 17, 2025
09:59 AM EDT, 03/17/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Monday its ongoing open label extension clinical trial for deramiocel showed a 52% reduction in the progression of Duchenne muscular dystrophy over a three-year period. In a cohort-matched external comparator analysis, the study showed that patients treated with deramiocel over three years experienced an average decline of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved